title: Functional nature of a novel mutant CYLD observed in pediatric lymphoblastic B-cell leukemia.
abstract: The Deubiquitinating enzyme, Cylindromatosis (CYLD), has been established as a crucial regulator of B-cells. The present study was addressed to identify the nature of CYLD-dependent RNomics in patients of pediatric age group with B-ALL. The study revealed the presence of a novel mutant CYLD of 55 kDa in these patients. The mutant CYLD displayed its ability to restrict the cells in G2 phase of cell cycle, down-regulate PLK-1 and block the nuclear translocation of BCL3. Based upon these results, we propose that this mutant CYLD has the capacity to act as a differential marker characteristic of B-cell lymphoblastic leukemia. Pediatr Blood Cancer 2015;62:1066-1069. © 2015 Wiley Periodicals, Inc.
authors: Departments of Experimental Medicine and Biotechnology, Post-graduate Institute of Medical Education and Research, Chandigarh, India.
authors: Mansi
authors: M
authors: Arora
authors: Deepak
authors: D
authors: Kaul
authors: Neelam
authors: N
authors: Varma
mesh_terms: D002648:Child; D000074749:Deubiquitinating Enzyme CYLD; D006801:Humans; D015448:Leukemia, B-Cell / Q000201:enzymology / Q000235:genetics*; D009154:Mutation; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000201:enzymology / Q000235:genetics*; D025521:Tumor Suppressor Proteins / Q000235:genetics*
chemical_list: D025521:Tumor Suppressor Proteins; C409984:CYLD protein, human; D000074749:Deubiquitinating Enzyme CYLD
keywords: BCL3; CYLD; PLK-1; human PBMCs; pediatric B-ALL